Xiang Gao1, Éilis J O'Reilly2, Michael A Schwarzschild2, Alberto Ascherio2. 1. From the Department of Nutritional Health (X.G.), The Pennsylvania State University, University Park; Department of Nutrition (E.J.O., A.A.), Harvard School of Public Health; Channing Division of Network Medicine (E.J.O., A.A.), Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; and Department of Neurology (M.A.S.), Massachusetts General Hospital and Harvard Medical School, Boston. xxg14@psu.edu. 2. From the Department of Nutritional Health (X.G.), The Pennsylvania State University, University Park; Department of Nutrition (E.J.O., A.A.), Harvard School of Public Health; Channing Division of Network Medicine (E.J.O., A.A.), Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; and Department of Neurology (M.A.S.), Massachusetts General Hospital and Harvard Medical School, Boston.
Abstract
OBJECTIVE: To examine whether higher plasma urate concentrations are associated with a lower risk of developing Parkinson disease (PD) and whether there is a sex difference in the potential urate-PD relationship. METHODS: We conducted a nested case-control study based on 90,214 participants of 3 ongoing US cohorts. We identified 388 new PD cases (202 men and 186 women) since blood collection, which were then matched to 1,267 controls. PD cases were confirmed by medical record review. Conditional logistic regression estimated relative risks (RRs) and 95% confidence intervals (95% CIs), after adjustment for age, smoking, caffeine intake, plasma concentrations of cholesterol and ferritin, and other covariates. We also conducted a meta-analysis to combine our study with 3 previously published prospective studies on urate and PD risk. RESULTS: In the present nested case-control study, the multivariate-adjusted RRs of PD comparing extreme quartiles of urate were 0.63 (95% CI 0.35, 1.10; ptrend = 0.049) in men and 1.04 (95% CI 0.61, 1.78; ptrend = 0.44) in women (pheterogeneity = 0.001). In the meta-analysis, the pooled RRs comparing 2 extreme quartiles of urate were 0.63 (95% CI 0.42, 0.95) in men and 0.89 (95% CI 0.57, 1.40) in women. CONCLUSION: We observed that men, but not women, with higher urate concentrations had a lower future risk of developing PD, suggesting that urate could be protective against PD risk or could slow disease progression during the preclinical stage of disease.
OBJECTIVE: To examine whether higher plasma urate concentrations are associated with a lower risk of developing Parkinson disease (PD) and whether there is a sex difference in the potential urate-PD relationship. METHODS: We conducted a nested case-control study based on 90,214 participants of 3 ongoing US cohorts. We identified 388 new PD cases (202 men and 186 women) since blood collection, which were then matched to 1,267 controls. PD cases were confirmed by medical record review. Conditional logistic regression estimated relative risks (RRs) and 95% confidence intervals (95% CIs), after adjustment for age, smoking, caffeine intake, plasma concentrations of cholesterol and ferritin, and other covariates. We also conducted a meta-analysis to combine our study with 3 previously published prospective studies on urate and PD risk. RESULTS: In the present nested case-control study, the multivariate-adjusted RRs of PD comparing extreme quartiles of urate were 0.63 (95% CI 0.35, 1.10; ptrend = 0.049) in men and 1.04 (95% CI 0.61, 1.78; ptrend = 0.44) in women (pheterogeneity = 0.001). In the meta-analysis, the pooled RRs comparing 2 extreme quartiles of urate were 0.63 (95% CI 0.42, 0.95) in men and 0.89 (95% CI 0.57, 1.40) in women. CONCLUSION: We observed that men, but not women, with higher urate concentrations had a lower future risk of developing PD, suggesting that urate could be protective against PD risk or could slow disease progression during the preclinical stage of disease.
Authors: S Jain; T G Ton; R M Boudreau; M Yang; E L Thacker; S Studenski; W T Longstreth; E S Strotmeyer; A B Newman Journal: Neuroepidemiology Date: 2011-06-16 Impact factor: 3.282
Authors: Reinaldo Uribe-San Martín; Pablo Venegas Francke; Felipe López Illanes; Alex Jones Gazmuri; Julio Salazar Rivera; Jaime Godoy Ferńndez; Julia Santín Martínez; Carlos Juri Journal: Mov Disord Date: 2013-03-27 Impact factor: 10.338
Authors: Xiqun Chen; Thomas C Burdett; Cody A Desjardins; Robert Logan; Sara Cipriani; Yuehang Xu; Michael A Schwarzschild Journal: Proc Natl Acad Sci U S A Date: 2012-12-17 Impact factor: 11.205
Authors: Isabel González-Aramburu; Pascual Sánchez-Juan; Silvia Jesús; Ana Gorostidi; Eduardo Fernández-Juan; Fátima Carrillo; María Sierra; Pilar Gómez-Garre; María T Cáceres-Redondo; José Berciano; Javier Ruiz-Martínez; Onofre Combarros; Pablo Mir; Jon Infante Journal: Mov Disord Date: 2013-05-27 Impact factor: 10.338
Authors: Michael A Schwarzschild; Alberto Ascherio; M Flint Beal; Merit E Cudkowicz; Gary C Curhan; Joshua M Hare; D Craig Hooper; Karl D Kieburtz; Eric A Macklin; David Oakes; Alice Rudolph; Ira Shoulson; Marsha K Tennis; Alberto J Espay; Maureen Gartner; Albert Hung; Grace Bwala; Richard Lenehan; Elmyra Encarnacion; Melissa Ainslie; Richard Castillo; Daniel Togasaki; Gina Barles; Joseph H Friedman; Lisa Niles; Julie H Carter; Megan Murray; Christopher G Goetz; Jeana Jaglin; Anwar Ahmed; David S Russell; Candace Cotto; John L Goudreau; Doozie Russell; Sotirios Andreas Parashos; Patricia Ede; Marie H Saint-Hilaire; Cathi-Ann Thomas; Raymond James; Mark A Stacy; Julia Johnson; Lisa Gauger; J Antonelle de Marcaida; Sheila Thurlow; Stuart H Isaacson; Lisbeth Carvajal; Jayaraman Rao; Maureen Cook; Charlise Hope-Porche; Lauren McClurg; Daniela L Grasso; Robert Logan; Constance Orme; Tori Ross; Alicia F D Brocht; Radu Constantinescu; Saloni Sharma; Charles Venuto; Joseph Weber; Ken Eaton Journal: JAMA Neurol Date: 2014-02 Impact factor: 18.302
Authors: Nikolaus R McFarland; Thomas Burdett; Cody A Desjardins; Matthew P Frosch; Michael A Schwarzschild Journal: Neurodegener Dis Date: 2013-02-28 Impact factor: 2.977
Authors: S Jesús; I Pérez; M T Cáceres-Redondo; F Carrillo; M Carballo; P Gómez-Garre; P Mir Journal: Eur J Neurol Date: 2012-05-12 Impact factor: 6.089
Authors: Sara Cipriani; Cody A Desjardins; Thomas C Burdett; Yuehang Xu; Kui Xu; Michael A Schwarzschild Journal: PLoS One Date: 2012-05-14 Impact factor: 3.240
Authors: Éilis J O'Reilly; Kjetil Bjornevik; Michael A Schwarzschild; Marjorie L McCullough; Laurence N Kolonel; Loic Le Marchand; Joann E Manson; Alberto Ascherio Journal: Amyotroph Lateral Scler Frontotemporal Degener Date: 2017-12-26 Impact factor: 4.092
Authors: Rachit Bakshi; Eric A Macklin; Albert Y Hung; Michael T Hayes; Bradley T Hyman; Anne-Marie Wills; Stephen N Gomperts; John H Growdon; Alberto Ascherio; Clemens R Scherzer; Michael A Schwarzschild Journal: J Parkinsons Dis Date: 2020 Impact factor: 5.568
Authors: Michael A Schwarzschild; Eric A Macklin; Rachit Bakshi; Shamik Battacharyya; Robert Logan; Alberto J Espay; Albert Y Hung; Grace Bwala; Christopher G Goetz; David S Russell; John L Goudreau; Sotirios A Parashos; Marie H Saint-Hilaire; Alice Rudolph; Joshua M Hare; Gary C Curhan; Alberto Ascherio Journal: Neurology Date: 2019-09-04 Impact factor: 9.910
Authors: Katherine C Hughes; Xiang Gao; Iris Y Kim; Eric B Rimm; Molin Wang; Marc G Weisskopf; Michael A Schwarzschild; Alberto Ascherio Journal: Mov Disord Date: 2016-10-27 Impact factor: 10.338
Authors: Iris Y Kim; Éilis J O'Reilly; Katherine C Hughes; Xiang Gao; Michael A Schwarzschild; Marian T Hannan; Rebecca A Betensky; Alberto Ascherio Journal: Neurology Date: 2018-04-11 Impact factor: 9.910